治疗中至重度斑块型银屑病新药:Risankizumab

New drug for Treatment of Moderate-to-severe Plaque Psoriasis:Risankizumab

白细胞介素23(interleukin-23,IL-23)为一种天然存在的细胞因子,参与炎症和免疫反应。Risankizumab是一种人源性抗IL-23单克隆抗体,可特异性与IL-23 p19亚基结合,减少炎症反应的发生。2019年4月23日,美国食品药物监督管理局批准Risankizumab用于治疗成人中重度斑块型银屑病。Risankizumab治疗相关的不良事件主要包括上呼吸道感染、头痛、疲劳、注射部位反应和真菌感染,患者一般均可良好耐受。本文从作用机制、药动学、临床应用及不良反应等方面对Risankizumab进行综述。

Interleukin-23(IL-23)is a natural cytokine involved in inflammation and immune response.Risankizumab is a humanized anti-IL-23 monoclonal antibody,which can bind with high affinity to IL-23 p19 subunit,thereby inhibiting the inflammatory response.It was approved for the treatment of patients with moderate-to-severe plaque psoriasis by the U.S.Food and Drug Administration on April 23,2019.The most common treatment-related adverse events include upper respiratory infections,headache,tiredness,injection site reactions,and fungal infections,and patients are generally well tolerated.This paper introduced risankizumab from the aspects of mechanism,pharmacokinetics,clinical application and adverse reactions.